Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Trial to Evaluate the Efficacy and Safety of Mocravimod as Adjuvant and Maintenance Treatment in Acute Myeloid Leukemia (AML) in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).